By Nana O 
Scientists at the University of Cambridge have achieved a significant breakthrough in understanding nerve regeneration, developing sophisticated lab-grown brain and spinal cord systems that accurately mimic the intricate pathways of movement signals in the human nervous system. This groundbreaking model has led to a paradigm shift in our understanding of nerve damage, revealing that injuries previously considered irreversible may, in fact, be amenable to repair under specific biological conditions. The implications of this discovery are profound, potentially offering new avenues for treating paralysis, neurological diseases, and other debilitating conditions.
The Intricate Dance of Neuronal Communication and the Loss of Regeneration
From the earliest stages of embryonic development, the human nervous system embarks on a remarkable journey of formation. Neurons, the fundamental building blocks of this complex network, establish intricate communication channels between the brain and the spinal cord. These vital signals, responsible for controlling everything from voluntary muscle movements to unconscious bodily functions, travel along specialized structures called axons. These long, slender nerve fibers act as the communication lines, transmitting electrochemical messages that orchestrate our every action.
However, as the central nervous system matures, it undergoes a profound change: a significant decline in its inherent ability to regenerate damaged axons. This developmental shift, while essential for establishing stable neural circuits, tragically means that injuries to the brain or spinal cord often result in permanent consequences. The inability of severed or damaged nerve fibers to regrow is a primary reason behind the devastating disabilities associated with such injuries, including paralysis and the loss of motor control. Furthermore, this regenerative deficit is increasingly implicated in the progression of devastating neurological diseases, such as motor neurone disease (also known as ALS) and multiple sclerosis (MS), where nerve damage leads to progressive functional decline.
Pioneering Organoid Technology: A Miniature Nervous System in the Lab
Building upon their previous work, researchers at the University of Cambridge, led by Dr. András Lakatos, have engineered a novel and highly sophisticated model system. In 2021, Dr. Lakatos and his team first unveiled miniature human brain models, or "brain organoids," meticulously grown from patient-derived stem cells. These pea-sized structures, remarkably resembling key regions of the cerebral cortex, provided an unprecedented platform for studying the molecular underpinnings of neurological disorders like motor neurone disease and for exploring potential preventative strategies.
The latest research, published in the prestigious journal Cell Reports, represents a significant expansion of this pioneering organoid technology. The team has now successfully constructed a miniature, interconnected human brain and spinal cord system. Recognizing the anatomical separation yet functional connectivity of these two crucial components of the central nervous system, the researchers ingeniously cultured the brain and spinal cord organoids separately in the laboratory. The critical observation was that axons originating from the brain organoid spontaneously extended across the physical gap, forming functional connections with the spinal cord organoid. This remarkable feat of bioengineering resulted in a nascent neural circuit capable of eliciting contractions in co-cultured muscle cell clusters, a compelling demonstration of its functional integrity.
Unveiling the Developmental Window for Nerve Regrowth
The research team meticulously maintained these miniature neural systems in their laboratory environment for an extended period, exceeding one year. This prolonged observation allowed them to meticulously track the regenerative capabilities of the developing axons. Their findings revealed a critical developmental window: up until approximately day 150 of development, a stage roughly analogous to the middle trimester of human gestation, damaged axons retained a significant capacity for regrowth. However, beyond this crucial developmental milestone, the neurons exhibited a dramatic and steep decline in their regenerative potential.
George Gibbons, a key researcher from the Department of Clinical Neurosciences at the University of Cambridge and the study’s first author, articulated the significance of this discovery: "Neurons derived from less mature organoids demonstrated the ability to regrow long fibers following injury, whereas those from more mature organoids showed a precipitous drop in their regenerative capacity. Essentially, the inherent limitation in regeneration is integrated into human neurons as they mature within the central nervous system."
The Molecular Switch Governing Axon Growth
To unravel the underlying mechanisms responsible for this developmental decline in regeneration, the scientists delved into the genetic activity of the neurons connecting the brain and spinal cord. Their comprehensive analysis identified a complex network of genes that appears to function as a biological "switch." This genetic circuitry effectively curtails axon growth as neurons mature and establish synaptic connections, a process crucial for refining neural function but detrimental to regeneration.
In a truly remarkable turn, the researchers were able to experimentally manipulate this genetic network. By strategically blocking key regulatory elements within this identified gene network, they observed a surprising restoration of axon growth capabilities in the neurons. This finding is of paramount importance, suggesting that the intrinsic limitations to regeneration are not immutable but rather are actively regulated and potentially reversible.
A Pharmaceutical Ally: Lynestrenol and Enhanced Nerve Repair
With a deeper understanding of the molecular pathways governing axon regeneration, the research team embarked on a quest to identify existing pharmaceutical compounds that could influence this newly discovered gene network. Their systematic search of a comprehensive database of drug compounds yielded a promising candidate: lynestrenol. This hormone drug, already approved and in clinical use for managing certain menstrual disorders and serving as a contraceptive, demonstrated a significant impact on the identified gene network.
Subsequent testing of lynestrenol on damaged neurons in their organoid models yielded encouraging results. The drug treatment significantly enhanced axon regrowth, underscoring its potential as a therapeutic agent for promoting nerve repair.
The scientists acknowledge that factors beyond intrinsic neuronal capacity, such as scar tissue formation and inflammation, can also impede nerve repair following injury. However, they emphasize the critical importance of understanding the neuron-specific biological mechanisms that limit regeneration. Previous research has indicated that younger, more regenerative neurons can navigate and grow through environments that typically inhibit repair at injury sites, further supporting the idea that intrinsic regenerative capacity is a key determinant.
Senior author Dr. András Lakatos elaborated on the study’s profound implications: "When the brain and spinal cord sustain damage, the nerve fibers responsible for transmitting movement signals from the brain to the spinal cord rarely regrow. This is the fundamental reason why paralysis is typically permanent. Our study has pinpointed a crucial window of development where this regenerative capacity becomes limited. Crucially, our model provides compelling evidence that this limitation can be reversed even after this developmental block has occurred."
He continued, "While lynestrenol itself might not be the ultimate solution for spinal cord repair, it unequivocally demonstrates that, in principle, it is possible to directly target human neurons and stimulate the regeneration of their axons. Although we still need to rigorously verify that this strategy can also facilitate the re-establishment of appropriate connections between brain and spinal cord cells, this breakthrough offers substantial hope that conditions previously deemed untreatable may one day become manageable."
The Indispensable Role of Human Organoids in Biomedical Research
The advent and refinement of organoid technology represent a significant leap forward in our ability to study human biology and disease. While animal models, such as mice and rats, have historically played a crucial role in biomedical research, inherent biological differences between species can limit the direct applicability of findings to human physiology and disease progression.
Human stem cell-derived organoids, such as those developed by Dr. Lakatos’s team, offer a more faithful recapitulation of human biology. This enhanced fidelity helps to bridge the critical gap between preclinical findings in animal models and the actual outcomes observed in human patients.
Dr. Lakatos further emphasized the value of this approach: "A substantial portion of our current understanding of nerve regeneration stems from studies conducted on rodents, whose neurons exhibit distinct behavioral patterns compared to human neurons. Our sophisticated organoid models serve as an invaluable tool for bridging this knowledge gap between animal studies and clinical observations in patients. Moreover, this advancement represents a significant contribution to the global efforts aimed at reducing the reliance on animal testing in research."
The University of Cambridge is at the forefront of organoid research, with ongoing studies utilizing these miniature biological systems to investigate a diverse range of medical conditions. These include efforts to develop regenerative therapies for damaged livers, to unravel the complexities of Crohn’s disease in pediatric patients, and to gain deeper insights into the earliest stages of human pregnancy.
This pioneering research was generously supported by funding from the UK Research and Innovation (UKRI) Medical Research Council and Spinal Research, underscoring the collaborative and well-supported nature of this transformative scientific endeavor. The potential for this work to translate into clinical applications offers a beacon of hope for millions affected by neurological damage and disease worldwide.
